Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1996;27:704-708

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Llambí, H. G.
Right arrow Articles by Taquini, C.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Llambí, H. G.
Right arrow Articles by Taquini, C.M.

(Hypertension. 1996;27:704-708.)
© 1996 American Heart Association, Inc.


Articles

Myocardial Contractility Is Modulated by Angiotensin II via Nitric Oxide

H. Gómez Llambí; F. Manni; P. La Padula; O.A. Carretero; C.M. Taquini

From Ininca, University of Buenos Aires (Argentina); and the Henry Ford Hospital, Detroit, Mich (O.A.C.).

Correspondence to Oscar A. Carretero, MD, Hypertension and Vascular Research Division, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202-2689.

Abstract We hypothesized that in cardiac muscles, angiotensin II partially inhibits the contractile response to ß-agonists. We studied the contractile response of isolated rat left ventricular papillary muscles to isoproterenol and the effect of angiotensin II on this response. We also investigated whether the effect of angiotensin II is mediated by bradykinin, prostaglandins, nitric oxide, and/or cGMP. Contractility of isolated papillary muscles was recorded with a force transducer, and rest tension, maximal developed tension (DT), maximal rate of rise in developed tension [T(+)], and maximal velocity of relaxation [T(-)] were measured (1) under basal conditions, (2) after pretreatment with various drugs, and (3) after cumulative doses of isoproterenol. Pretreatment groups included (1) vehicle (controls); (2) angiotensin II; (3) angiotensin II and N{omega}-nitro-L-arginine, an inhibitor of nitric oxide release; (4) L-arginine, the substrate for nitric oxide synthase; (5) L-arginine and N{omega}-nitro-L-arginine; (6) 8-bromo-cGMP, analogous to the second messenger of nitric oxide; (7) angiotensin II and icatibant (Hoe 140), a bradykinin B2 antagonist; and (8) angiotensin II and indomethacin, a cyclooxygenase inhibitor. There were no differences in contractile parameters before and after any of the pretreatments. Isoproterenol increased DT, T(+), and T(-), and these effects were attenuated by angiotensin II, L-arginine, and 8-bromo-cGMP. The effects of angiotensin II and L-arginine were blocked by inhibition of nitric oxide release with N{omega}-nitro-L-arginine. Neither the bradykinin B2 antagonist nor the cyclooxygenase inhibitor altered the effects of angiotensin II. We concluded that angiotensin II partially inhibits the contractile response of cardiac papillary muscles to isoproterenol. This effect is likely mediated by nitric oxide release, perhaps acting via cGMP. Kinins and prostaglandins do not appear to participate in the inhibitory effect of angiotensin II. Attenuation of the contractile effect of isoproterenol by angiotensin II may help explain why cardiac function improves in heart failure after blockade of the renin-angiotensin system.


Key Words: angiotensin II • isoproterenol • kinins • nitric oxide • myocardial contraction • L-NA




This article has been cited by other articles:


Home page
Exp PhysiolHome page
P. Castro-Chaves, R. Fontes-Carvalho, M. Pintalhao, P. Pimentel-Nunes, and A. F. Leite-Moreira
Angiotensin II-induced increase in myocardial distensibility and its modulation by the endocardial endothelium in the rabbit heart
Exp Physiol, June 1, 2009; 94(6): 665 - 674.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Kobayashi, T. Higashi, K. Hara, H. Shirataki, and H. Matsuoka
Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl salt-sensitive hypertensive rats
Cardiovasc Res, December 1, 1999; 44(3): 518 - 526.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
X.-P. Yang, Y.-H. Liu, E. G. Shesely, M. Bulagannawar, F. Liu, and O. A. Carretero
Endothelial Nitric Oxide Gene Knockout Mice : Cardiac Phenotypes and the Effect of Angiotensin-Converting Enzyme Inhibitor on Myocardial Ischemia/Reperfusion Injury
Hypertension, July 1, 1999; 34(1): 24 - 30.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. Kurtz and C. Wagner
Role of nitric oxide in the control of renin secretion
Am J Physiol Renal Physiol, December 1, 1998; 275(6): F849 - F862.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. Wang
Cardiac sympathetic afferent stimulation by bradykinin in heart failure: role of NO and prostaglandins
Am J Physiol Heart Circ Physiol, September 1, 1998; 275(3): H783 - H788.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. A. Kelly, J.-L. Balligand, and T. W. Smith
Nitric Oxide and Cardiac Function
Circ. Res., September 1, 1996; 79(3): 363 - 380.
[Full Text]